AR065829A1 - Plegamiento de proteinas - Google Patents
Plegamiento de proteinasInfo
- Publication number
- AR065829A1 AR065829A1 ARP070104045A ARP070104045A AR065829A1 AR 065829 A1 AR065829 A1 AR 065829A1 AR P070104045 A ARP070104045 A AR P070104045A AR P070104045 A ARP070104045 A AR P070104045A AR 065829 A1 AR065829 A1 AR 065829A1
- Authority
- AR
- Argentina
- Prior art keywords
- biologically active
- growth factor
- functional analogs
- beta transformation
- transformation growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se relaciona con un método para el plegado de un factor de crecimiento de transformacion beta, o uno de sus análogos funcionales, a fin de obtener una forma biologicamente activa, dímera. El método comprende la adicion de factor decrecimiento monomero, no plegado, solubilizado, a una solucion que contiene ácido 2-(ciclohexilamino)-etanosulfonico (CHES), o uno de sus análogos funcionales, y un sistema de oxidorreduccion de sulfhidrilo/disulfuro de bajo peso molecular. Lasolucion luego se incuba en condiciones adecuadas para la generacion de factor de crecimiento de transformacion beta biologicamente activo, dímero.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0604964.7A GB0604964D0 (en) | 2006-03-11 | 2006-03-11 | Protein folding |
| PCT/GB2007/000814 WO2007104934A2 (en) | 2006-03-11 | 2007-03-09 | Protein folding |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065829A1 true AR065829A1 (es) | 2009-07-08 |
Family
ID=36241465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104045A AR065829A1 (es) | 2006-03-11 | 2007-09-12 | Plegamiento de proteinas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7893221B2 (es) |
| EP (1) | EP1996605A2 (es) |
| JP (1) | JP2009529571A (es) |
| KR (1) | KR20080106449A (es) |
| CN (1) | CN101437837A (es) |
| AR (1) | AR065829A1 (es) |
| AU (1) | AU2007226334A1 (es) |
| BR (1) | BRPI0708751A2 (es) |
| CA (1) | CA2645109A1 (es) |
| GB (1) | GB0604964D0 (es) |
| IL (1) | IL193696A0 (es) |
| MX (1) | MX2008011706A (es) |
| NO (1) | NO20084188L (es) |
| RU (1) | RU2008140113A (es) |
| WO (1) | WO2007104934A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0604938D0 (en) | 2006-03-11 | 2006-04-19 | Renovo Ltd | Proteins, nucleic acids and medicaments |
| GB0604966D0 (en) | 2006-03-11 | 2006-04-19 | Renovo Ltd | Medicaments and proteins |
| EP3744728A1 (en) | 2013-02-12 | 2020-12-02 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
| CN106353445A (zh) * | 2016-09-30 | 2017-01-25 | 王荔 | 一种iptg含量的检测方法 |
| CN108753753B (zh) * | 2018-05-28 | 2022-04-22 | 中国林业科学研究院林业研究所 | Lrr受体激酶-pxy的纯化方法 |
| KR20240064367A (ko) * | 2022-11-04 | 2024-05-13 | 주식회사 대웅제약 | TGF-β3 단백질의 정제방법 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4051848A (en) | 1976-03-01 | 1977-10-04 | Levine Norman S | Synthetic skin wound dressing |
| IL78197A (en) | 1985-03-22 | 1991-07-18 | Genentech Inc | Nucleic acid encoding tgf-beta and its uses |
| US6559123B1 (en) | 1985-04-19 | 2003-05-06 | Osi Pharmaceuticals, Inc. | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof |
| US5135915A (en) | 1988-10-14 | 1992-08-04 | Genentech, Inc. | Method for the treatment of grafts prior to transplantation using TGF-.beta. |
| AU6870791A (en) | 1989-10-18 | 1991-05-16 | Creative Biomolecules, Inc. | Biosynthetic constructs of tgf-beta |
| GB8927546D0 (en) * | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| US6054122A (en) | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| GB9206861D0 (en) | 1992-03-28 | 1992-05-13 | Univ Manchester | Wound healing and treatment of fibrotic disorders |
| AU3943793A (en) | 1992-04-01 | 1993-11-08 | Whittier Institute For Diabetes And Endocrinology, The | Methods of inhibiting or enhancing scar formation in the CNS |
| US5411940A (en) | 1993-09-29 | 1995-05-02 | Alcon Laboratories, Inc. | Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma |
| US5399677A (en) * | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
| TW440566B (en) | 1994-07-25 | 2001-06-16 | Novartis Ag | Novel process for the production of biologically active dimeric protein |
| WO1997005166A1 (en) | 1995-07-25 | 1997-02-13 | Novartis Ag | Transforming growth factor beta crystals |
| EP0943690B1 (en) | 1995-12-21 | 2006-11-29 | Ajinomoto Co., Inc. | Method for refolding human activin a |
| CA2251129A1 (en) | 1996-05-03 | 1997-11-13 | Innogenetics N.V. | New medicaments containing gelatin cross-linked with oxidized polysaccharides |
| US20020052026A1 (en) | 1997-10-08 | 2002-05-02 | Steven M. Vicik | Methods of refolding proteins |
| US6677432B1 (en) | 1998-10-07 | 2004-01-13 | Stryker Corporation | Mutations of the C-terminal portion of TGF-β superfamily proteins |
| CA2344269A1 (en) | 1998-10-07 | 2000-04-13 | Syngenta Participations Ag | Therapeutically active proteins in plants |
| EP1161257A2 (en) | 1999-03-17 | 2001-12-12 | Novartis AG | Pharmaceutical compositions comprising tgf-beta |
| WO2000056879A1 (en) | 1999-03-22 | 2000-09-28 | Universität Zürich | TRANSFORMING GROWTH FACTOR (TFG) β SUPERFAMILY ANTAGONISTS |
| AR027765A1 (es) | 2000-04-03 | 2003-04-09 | Monsanto Technology Llc | Expresion y purificacion de polipeptidos bioactivos autenticos a partir de plantas |
| EP1279677B1 (en) | 2000-04-25 | 2007-03-07 | Otsuka Pharmaceutical Co., Ltd. | Gd3-mimetic peptides |
| US20040078851A1 (en) | 2000-05-02 | 2004-04-22 | Ning Huang | Production of human growth factors in monocot seeds |
| DE10026713A1 (de) | 2000-05-30 | 2001-12-06 | Walter Sebald | Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta |
| AU2001238091A1 (en) | 2000-08-09 | 2002-02-18 | Curis, Inc. | Tgf-beta therapeutics, compositions and methods of use |
| JP2004525930A (ja) | 2001-03-23 | 2004-08-26 | バイオファーム・ゲゼルシャフト・ツア・バイオテクノロジシェン・エントヴィックルング・フォン・ファーマカ・ミット・ベシュレンクテル・ハフツング | 皮膚関連疾患の治療及び診断のためのＴＧＦ−βスーパーファミリーのサイトカインの使用 |
| US20030033637A1 (en) | 2001-06-05 | 2003-02-13 | Croptech Corporation | Gene expression and production of TGF-beta proteins including bioactive mullerian inhibiting substance from plants |
| US20060026704A1 (en) | 2002-09-27 | 2006-02-02 | Guillermo Selman-Housein Sosa | Vector for the production of transplastomic angiosperm plants |
| AU2005277227B2 (en) * | 2004-08-19 | 2011-10-06 | Biogen Ma Inc. | Refolding transforming growth factor beta family proteins |
| WO2006118617A2 (en) | 2004-12-23 | 2006-11-09 | Chlorogen, Inc. | EXPRESSING TGF-β PROTEINS IN PLANT PLASTIDS |
| EP1915169A2 (en) | 2005-07-12 | 2008-04-30 | Renovo Limited | Pharmaceutical compositions comprising a tgf-beta superfamily member |
| GB0514262D0 (en) | 2005-07-12 | 2005-08-17 | Renovo Ltd | Promotion of epithelial regeneration |
| GB0604938D0 (en) | 2006-03-11 | 2006-04-19 | Renovo Ltd | Proteins, nucleic acids and medicaments |
| GB0604966D0 (en) | 2006-03-11 | 2006-04-19 | Renovo Ltd | Medicaments and proteins |
| GB0617816D0 (en) | 2006-09-11 | 2006-10-18 | Renovo Ltd | Nucleic acids and methods of protein expression |
-
2006
- 2006-03-11 GB GBGB0604964.7A patent/GB0604964D0/en not_active Ceased
-
2007
- 2007-03-09 JP JP2008558878A patent/JP2009529571A/ja active Pending
- 2007-03-09 BR BRPI0708751-9A patent/BRPI0708751A2/pt not_active IP Right Cessation
- 2007-03-09 CN CNA2007800163539A patent/CN101437837A/zh active Pending
- 2007-03-09 US US12/282,456 patent/US7893221B2/en not_active Expired - Fee Related
- 2007-03-09 KR KR1020087023404A patent/KR20080106449A/ko not_active Application Discontinuation
- 2007-03-09 RU RU2008140113/13A patent/RU2008140113A/ru not_active Application Discontinuation
- 2007-03-09 WO PCT/GB2007/000814 patent/WO2007104934A2/en active Application Filing
- 2007-03-09 MX MX2008011706A patent/MX2008011706A/es unknown
- 2007-03-09 EP EP07705326A patent/EP1996605A2/en not_active Withdrawn
- 2007-03-09 CA CA002645109A patent/CA2645109A1/en not_active Abandoned
- 2007-03-09 AU AU2007226334A patent/AU2007226334A1/en not_active Abandoned
- 2007-09-12 AR ARP070104045A patent/AR065829A1/es not_active Application Discontinuation
-
2008
- 2008-08-26 IL IL193696A patent/IL193696A0/en unknown
- 2008-10-07 NO NO20084188A patent/NO20084188L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1996605A2 (en) | 2008-12-03 |
| CN101437837A (zh) | 2009-05-20 |
| CA2645109A1 (en) | 2007-09-20 |
| US20090181430A1 (en) | 2009-07-16 |
| WO2007104934A2 (en) | 2007-09-20 |
| US7893221B2 (en) | 2011-02-22 |
| WO2007104934A3 (en) | 2008-01-03 |
| JP2009529571A (ja) | 2009-08-20 |
| RU2008140113A (ru) | 2010-04-20 |
| AU2007226334A1 (en) | 2007-09-20 |
| GB0604964D0 (en) | 2006-04-19 |
| IL193696A0 (en) | 2011-08-01 |
| BRPI0708751A2 (pt) | 2011-06-28 |
| KR20080106449A (ko) | 2008-12-05 |
| MX2008011706A (es) | 2008-09-26 |
| NO20084188L (no) | 2008-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065829A1 (es) | Plegamiento de proteinas | |
| CO6251275A2 (es) | Formulaciones de inmunoglobulina liofilizadas y metodos para su preparacion | |
| CR11005A (es) | Formulaciones estables de anticuerpos | |
| ES2531083T3 (es) | Formulaciones estables de polipéptidos y usos de las mismas | |
| NZ629204A (en) | Anti-vla1 (cd49a) antibody pharmaceutical compositions | |
| MX2010004399A (es) | Formulacion liquida que contiene anticuerpos en una alta concentracion. | |
| CY1118243T1 (el) | Νεα κατασκευασματα μεταφορεα και μορια συζευγματος φορτιου μεταφορεα | |
| BR112012022223A2 (pt) | formulações de proteína concentrada e usos das mesmas | |
| BR112015008186A2 (pt) | formulação de um anticorpo estável e de baixa viscosidade | |
| PE20120648A1 (es) | Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1 | |
| CO6361952A2 (es) | Formulación de anticuerpo | |
| AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
| AR067011A1 (es) | Formulaciones de anticuerpos | |
| SV2019005808A (es) | Nuevos analógos de urocortina - 2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal cronica | |
| BR112013002764A8 (pt) | formulações esatabilizadas contendo anticorpos anti-ngf | |
| PE20120204A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| AR084725A1 (es) | Composiciones bioactivas de chromobacterium y metabolitos | |
| NO20083910L (no) | Forbedret prodroge av CC-1065 analoger | |
| EA200870615A1 (ru) | Производные лептомицина | |
| BR112013020609A2 (pt) | 2-hidróxi-4-(metiltio) butironitrila estável em armazenamento | |
| ES2531385T3 (es) | Formulación que comprende un anticuerpo contra la selectina P | |
| EA201491155A1 (ru) | Новые мутантные про-нрф и их применение для получения бета-нрф | |
| AR080884A1 (es) | Conjugados de insulina-sirna | |
| CY1116941T1 (el) | Βελτιωση της βιοδιαθεσιμοτητας δραστικων ουσιων με δραστικη ομαδα αμιδινης σε φαρμακα | |
| BRPI0905847B8 (pt) | composição farmacêutica injetável |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |